[1] | Belyalov F.I. Ischemic heart disease and impaired renal function. Rational pharmacotherapy in cardiology 2017; 13(3): 409-415. |
[2] | Breidthardt, T. Diagnostic and prognostic value of cystatin C in acute heart failure / T. Breidthardt, Z. Sabti, R. Ziller, F. Rassouli, R. Twerenbold, N. Kozhuharov, E. Gayat, S. Shrestha, S. Barata, P. Badertscher, J. Boeddinghaus, T. Nestelberger, C. Mueller // Clin Biochem. - 2017. - Vol. 50, № 18. -Р. 1007-1013. |
[3] | Correa, S. Cystatin C for risk stratification in patients after an acute coronary syndrome / S. Correa, D.A. Morrow, E. Braunwald, R.Y. Davies, E.L. Goodrich, S.A. Murphy, C.P. Cannon, M.L. O'Donoghue // J Am Heart Assoc. - 2018. - Vol. 7, № 20. |
[4] | Delanaye P, Cavalier E, Krzesinski JM et al Cystatin C, renal function, and cardiovascular risk"Ann. Intern. Med. 2008, 148 (4): 323. |
[5] | Deng Y., Wang L., Hou Y. et al. The influence of glycemic status on the performance of cystatin C for acute kidney injury detection in the critically ill // Ren. Fail. - 2019. -Vol. 41 (1)—P. 139–149. |
[6] | Deo R, Fyr CL, Fried LF, et al.. "Kidney dysfunction and fatal cardiovascular disease--an association independent of atherosclerotic events: results from the Health, Aging, and Body Composition (Health ABC) study". Am. Heart J. 2008. 155 (1): 62–8. |
[7] | Eckel, R.H. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk [Text] / R.H. Eckel, J.M. Jakicic, J.D. Ard, N.H. Miller, V.S. Hubbard, C.A. Nonas, J.M. de Jesus, F.M. Sacks, I.-M. Lee, Jr.S.C. Smith, A.H. Lichtenstein, L.P. Svetkey, C.M. Loria, T.W. Wadden, B.E. Millen, S.Z. Yanovski // Journal of the American College of Cardiology. – 2013, doi: 10.1016/j.jacc.2013.11.003. |
[8] | Elsayed, M.S. Serum cystatin C as an indicator for early detection of diabetic nephropathy in type 2 diabetes mellitus / M.S. Elsayed, A. El Badawy, A. Ahmed, R. Omar, A. Mohamed // Diabetes Metab Syndr. - 2019. - Vol. 13, № 1. -Р. 374-381. |
[9] | Gadaev A.G., Rakhimova M.E., Turgunova M.U. The role of cystatin c in assessing the functional state of the kidneys in patients with coronary heart disease Therapeutic Bulletin of Uzbekistan. 2022. No. 4. C-104-110.е. |
[10] | Glavnova O.B., Yarmolinskaya M.I., Suslova S.V., Borovik N.V. Possibilities of using cystatin C in the diagnosis of various diseases // Journal of Obstetrics and Women's Diseases. - 2018. - T. 67. - No. 4. - S. 40–47. doi: 10.17816/JOWD67440-47. |
[11] | Kim S., Hwang S., Jang H. R. et al. Creatinine- and cystatin C-based estimated glomerular filtration rate slopes for the prediction of kidney outcome: a comparative retrospective study // BMC Nephrol. -2019. -Vol. 20 (1) - P. 214. |
[12] | Liu, X. Is the chronic kidney disease epidemiology collaboration creatinine-cystatin C equation useful for glomerular filtration rate estimation in the elderly / X. Liu, H. Ma, H. Huang [et al] // Clin Interv Aging. - 2013. - № 8. -Р. 1387-1391. |
[13] | Luis-Lima, S. An overview of errors and flaws of estimated GFR versus true GFR in patients with diabetes mellitus / S. Luis-Lima, E. Porrini //Nephron. - 2017. - Vol. 136, № 4. - Р. 287-291. |
[14] | Osaki T., Satoh M., Tanaka F. et al. The Value of a Cystatin C-based Estimated Glomerular Filtration Rate for Cardiovascular Assessment in a General Japanese Population: Results from the Iwate Tohoku Medical Megabank Project // J. Epidemiol. - 2019. -May 25. doi: 10.2188/jea.JE20180274. [Epub ahead of print]. |
[15] | Parsh J., Seth M., Aronow H., et al. Choice of Estimated Glomerular Filtration Rate Equation Impacts Drug-Dosing Recommendations and Risk Stratification in Patients With Chronic Kidney Disease Undergoing PCI. J Am Coll Cardiol. 2015; 65(25): 2714-23. |
[16] | Porrini, E. Remuzzi estimated GFR: time for a critical appraisal /E. Porrini,P. Ruggenenti, S. Luis-Lima, F. Carrara, A. Jiménez, A.P.J. de Vries, A. Torres, F. Gaspari // GNat Rev Nephrol. - 2018. |
[17] | Ravn, B. Superiority of serum cystatin C over creatinine in prediction of long-term prognosis at discharge from ICU / B. Ravn, J.R. Prowle, J. Mårtensson, C.R. Martling, M. Bell // Crit Care Med. - 2017. -Vol. 45, № 9. - Р. 932-940. |
[18] | Scheen A.J. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol 2013; 9 (5): 529-550. |
[19] | Shen, G. Increased cystatin C level in ST-elevation myocardial infarction predisposes the prognosis of angioplasty / G. Shen, H. Zhu, H. Ding,C. Sun, K. Zhou, Y. Fan, T. Li, M. Men, Y. Chen, Q. Lu, A. Ma // Am J. Med Sci. - 2018. - Vol. 355, № 6. - Р. 530-536. |
[20] | Shlipak MG, Katz R, Kestenhbaum B, et al..: Rate of kidney function decline in older adults: a comparison using creatinine and cystatin C. Am J Nephrol 2009; 30: 171–8. |
[21] | Waldeyer C., Karakas M., Scheurle C., et al. The predictive value of different equations for estimation of glomerular filtration rate in patients with coronary artery disease — Results from the AtheroGene study. Int J Card. 2016; 221: 908-13. |